The Effects Of Remote Organ Ischemic Preconditioning On Systemic Inflammatory And Glycocalyx Inte… (NCT04216407) | Clinical Trial Compass
CompletedNot Applicable
The Effects Of Remote Organ Ischemic Preconditioning On Systemic Inflammatory And Glycocalyx Integrity Parameters
Turkey (Türkiye)22 participantsStarted 2019-12-05
Plain-language summary
Ischemia-reperfusion (IR) injury during liver transplantation is one of the major causes of mortality and morbidity associated with transplantation. Remote organ ischemic preconditioning (RIPC) is one of the most investigated practices to reduce IR injury. In this study, for the first time in the clinic, the effect of RIPC will be evaluated via both systemic inflammation parameters and also parameters showing glycocalyx integrity, on living-donor liver recipients.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients followed up by Acıbadem Hospital Organ Transplantation Center
* Patients accepted to participate in the study
* Older than 18 years of age
* ASA class III
* MELD score \>12
* Scheduled for elective liver transplantation surgery from a living donor
Exclusion Criteria:
* Patients undergoing re-transplantation
* Under the age of 18 years
* Patients undergoing emergency surgery
* Patients with hepatorenal or hepatopulmonary syndrome
* Patients receiving mechanical ventilation support in the ICU
* Patients refusing to participate
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Tumor necrosis factor-alpha (TNF-alpha)
Timeframe: Postoperative early period (6 hours after intensive care unite admission)
2
Intercellular adhesion molecule-1 (ICAM-1)
Timeframe: Postoperative early period (6 hours after intensive care unite admission)
3
Hypoxia-induced factor-1 (HIF-1)
Timeframe: Postoperative early period (6 hours after intensive care unite admission)
4
Interleukin-8 (IL-8)
Timeframe: Postoperative early period (6 hours after intensive care unite admission)
5
Syndecan-1 (SDC-1)
Timeframe: Postoperative early period (6 hours after intensive care unite admission)